Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib plus Andamertinib in EGFR-TKI–resistant MET-overexpressing NSCLC
ChiCTR2600117889Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebreltinib and andamertinib in non-small cell lung cancer (NSCLC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Objective response rate and Progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
vebreltinibandamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600117889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117889.